Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

How Does Myasthenia Gravis Affect Your Muscles?

At a Glance

Myasthenia gravis causes muscle weakness by producing rogue antibodies that attack the connection between your nerves and muscles. These antibodies block or destroy the receptors needed to receive movement signals, preventing normal muscle contraction and causing rapid fatigue.

To understand what myasthenia gravis (MG) does to your muscles, it helps to imagine a person ringing a doorbell. In a healthy body, your nerve is the finger, and your muscle is the house. When your brain wants to move a muscle, the nerve (the finger) releases a chemical signal called acetylcholine to press the muscle’s doorbell. When the doorbell rings, the muscle contracts [1][2].

In myasthenia gravis, your immune system produces autoantibodies—rogue proteins that mistakenly attack this connection. Depending on your specific type of MG, these autoantibodies are either blocking the doorbell button, breaking the doorbell’s wiring, or pulling the doorbell right off the wall [3]. Because of this damage, the acetylcholine signal cannot ring the bell, and the muscle cannot contract normally, leading to weakness [4].

Pulling the Doorbell Off the Wall (AChR-MG)

For the majority of people with MG, the immune system produces anti-AChR antibodies. These antibodies target the actual doorbell—the acetylcholine receptors on the surface of the muscle. They can cause damage in three distinct ways:

  1. Blocking the button: Some antibodies simply sit on top of the receptor, directly blocking the chemical signal from pressing it [3].
  2. Pulling it inside: They can bind receptors together, prompting the muscle to pull them inside and break them down [5].
  3. Destroying the wall: Once they attach, they can trigger a heavy-duty immune response (the complement system) that physically damages the surface of the muscle cell, flattening out the area where the receptors live [3][6].

In our analogy, this is like ripping the doorbell off the wall. The nerve is still pushing the signal, but there are not enough buttons left to press.

Breaking the Doorbell’s Wiring (MuSK and LRP4-MG)

Some people have different types of MG, such as those with anti-MuSK or anti-LRP4 antibodies. MuSK and LRP4 are proteins responsible for anchoring the receptors in place and keeping them tightly clustered together [7][8]. When autoantibodies attack these proteins, they act like a wedge that disrupts this essential scaffolding [9].

Instead of directly destroying the doorbell, this attack unplugs the wiring and prevents the muscle from building and organizing its receptors properly [10]. The signal fails because the mechanism is broken. Because the underlying damage is different, treatments that work for AChR-MG may not be effective for MuSK-MG [11]. However, there is no need to worry if you have this type—there are highly effective, targeted treatments available specifically for MuSK-MG.

(Note: Some patients are seronegative, meaning their specific autoantibody hasn’t been identified yet on standard blood tests. If this is you, the fundamental disruption to the connection between nerve and muscle still applies to you, even if standard tests cannot yet spot the exact rogue protein).

Why Your Muscles Get Fatigued

Because of this damage at the neuromuscular junction (the small space between the nerve and the muscle), your muscles do not receive a consistent, strong signal to move [12].

When you try to use the affected muscles repeatedly—like chewing, walking, or keeping your eyes open—the nerve naturally releases slightly less acetylcholine with each repeated signal. In a healthy person, there are plenty of receptors to catch that smaller signal. But in MG, with so many “doorbells” missing or blocked, the signal quickly drops below the threshold needed to ring the bell [13].

This is why your muscles become increasingly exhausted the more you use them (fatigable weakness), and why resting can temporarily restore your strength. To manage this fatigue effectively, try to pace yourself by taking strategic breaks during physically demanding activities to let your ‘doorbells’ reset.

Common questions in this guide

Why do my muscles get so tired when I have myasthenia gravis?
In myasthenia gravis, missing or blocked muscle receptors cause nerve signals to drop below the threshold needed for movement. As you repeatedly use a muscle, the nerve naturally releases less of the signal, leading to rapid exhaustion known as fatigable weakness.
How do AChR antibodies cause muscle weakness?
AChR antibodies attack the acetylcholine receptors on your muscles. They can block the chemical signals from your nerves, pull the receptors inside the muscle, or trigger an immune response that physically damages the muscle surface.
What is the difference between AChR and MuSK myasthenia gravis?
While AChR antibodies directly attack the receptors on the muscle, MuSK and LRP4 antibodies disrupt the proteins that hold these receptors in place. This breaks the muscle's scaffolding, preventing it from organizing receptors properly and requiring different targeted treatments.
Does resting help restore muscle strength in myasthenia gravis?
Yes, resting temporarily restores muscle strength because it allows the neuromuscular junction time to reset. This rest period compensates for the missing or blocked receptors that cause severe fatigue during repetitive activities.
What does it mean to be seronegative for myasthenia gravis?
Being seronegative means standard blood tests cannot yet identify the specific rogue antibody causing your condition. However, the fundamental disruption to the connection between your nerves and muscles still occurs in the exact same way.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific antibody type (AChR, MuSK, LRP4, or seronegative) did I test positive for?
  2. 2.How does my specific antibody profile change which treatments will be most effective for my neuromuscular junction?
  3. 3.Are there common medications or supplements I should avoid that might further block my acetylcholine receptors?
  4. 4.How can we measure if my current treatment is actually helping repair the connection between my nerves and muscles?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders.

    Verschuuren JJ, Palace J, Murai H, et al.

    The Lancet. Neurology 2022; (21(2)):189-202 doi:10.1016/S1474-4422(21)00463-4.

    PMID: 35065041
  2. 2

    Cholesterol in myasthenia gravis.

    Paz ML, Barrantes FJ

    Archives of biochemistry and biophysics 2021; (701()):108788 doi:10.1016/j.abb.2021.108788.

    PMID: 33548213
  3. 3

    Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.

    Fichtner ML, Jiang R, Bourke A, et al.

    Frontiers in immunology 2020; (11()):776 doi:10.3389/fimmu.2020.00776.

    PMID: 32547535
  4. 4

    Animal models of myasthenia gravis.

    Sikorski PM, Kusner LL

    International review of neurobiology 2025; (182()):145-160 doi:10.1016/bs.irn.2025.04.029.

    PMID: 40675733
  5. 5

    Analysis of nAChR Autoantibodies Against Extracellular Epitopes in MG Patients.

    Michail M, Zouvelou V, Belimezi M, et al.

    Frontiers in neurology 2022; (13()):858998 doi:10.3389/fneur.2022.858998.

    PMID: 35418927
  6. 6

    Myasthenia gravis: the role of complement at the neuromuscular junction.

    Howard JF

    Annals of the New York Academy of Sciences 2018; (1412(1)):113-128 doi:10.1111/nyas.13522.

    PMID: 29266249
  7. 7

    Lrp4 in astrocytes modulates glutamatergic transmission.

    Sun XD, Li L, Liu F, et al.

    Nature neuroscience 2016; (19(8)):1010-8 doi:10.1038/nn.4326.

    PMID: 27294513
  8. 8

    Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis.

    Basile U, Napodano C, Gulli F, et al.

    International journal of molecular sciences 2021; (22(17)) doi:10.3390/ijms22179142.

    PMID: 34502051
  9. 9

    MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.

    Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2019; (6(3)):e547 doi:10.1212/NXI.0000000000000547.

    PMID: 30882021
  10. 10

    Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.

    Verschuuren JJGM, Plomp JJ, Burden SJ, et al.

    Annals of the New York Academy of Sciences 2018; (1413(1)):111-118 doi:10.1111/nyas.13543.

    PMID: 29356029
  11. 11

    The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.

    Ghazanfari N, Trajanovska S, Morsch M, et al.

    Annals of the New York Academy of Sciences 2018; (1412(1)):54-61 doi:10.1111/nyas.13513.

    PMID: 29125188
  12. 12

    Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.

    Theissen L, Schroeter CB, Huntemann N, et al.

    Cells 2024; (13(6)) doi:10.3390/cells13060508.

    PMID: 38534352
  13. 13

    Single-cell transcriptomics and network pharmacology reveal therapeutic targets of Jianpi Yiqi Bugan Yishen decoction in immune cell subsets of children with myasthenia gravis.

    Liu P, Qi G, Gu S, et al.

    Translational pediatrics 2022; (11(12)):1985-2003 doi:10.21037/tp-22-593.

    PMID: 36643680

This page provides educational information about how myasthenia gravis affects muscle function. Always consult your neurologist for medical advice and personalized treatment options.

Get notified when new evidence is published on Myasthenia gravis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.